Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Cosmo presents strong H1 2023 operational and financial results
Cosmo presents strong H1 2023 operational and financial results
Cosmo presents strong H1 2023 operational and financial results
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Methodist Jennie Edmundson Hospital Partners With Acadia Healthcare to Build New Behavioral Health Hospital in Council Bluffs: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Methodist Jennie Edmundson Hospital Partners With Acadia Healthcare to Build New Behavioral Health Hospital in Council Bluffs


According to American Hospital Directory data, there is a shortfall of more than 300 inpatient behavioral health beds in Iowa and Nebraska.



To address this need, Methodist Jennie Edmundson

Acadia Healthcare Forms Joint Venture Partnership With Nebraska Methodist Health System: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Forms Joint Venture Partnership With Nebraska Methodist Health System


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) announced today that it has formed a joint venture with Nebraska Methodist Health System to build a state-of-the-art, 96-bed behavioral health

Convatec Group PLC: HOL-Holding(s) in Company
Convatec Group PLC: HOL-Holding(s) in Company
Convatec Group PLC: HOL-Holding(s) in Company
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Almirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business: https://mms.businesswire.com/media/20221109006035/en/1631769/5/ALM_AW_LOGO_Tagline_MV_Positive_RGB_%281%29.jpg
Almirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business


Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its H1 2023 financial results.



Financial highlights (€ rounded million)


 


H1 2023

 

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer


Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis for the phase 3 PANOVA-3 clinical trial evaluating the safety and efficacy of Tumor Treating Fields

EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
Premier, Inc. to Report Fiscal 2023 Fourth-Quarter and Full-Year Results and Host Conference Call on August 22, 2023: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. to Report Fiscal 2023 Fourth-Quarter and Full-Year Results and Host Conference Call on August 22, 2023


Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2023 fourth quarter and full year on Tuesday, August 22, 2023, at approximately 6:30 a.m. ET. The

Charles River Laboratories Schedules Second-Quarter 2023 Earnings Release and Conference Call: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Schedules Second-Quarter 2023 Earnings Release and Conference Call


Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2023 financial results on Wednesday, August 9th, before the market opens. A conference call has been scheduled

Acadia Healthcare Opens the First of Two Hospitals Developed in Partnership With Geisinger: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Opens the First of Two Hospitals Developed in Partnership With Geisinger


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the opening of its newest operating joint venture hospital, Geisinger Behavioral Health Center Northeast, located in Moosic

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
First Half of 2023 Sees ICON Recognised for CRO Excellence, Alongside Industry Awards as an Employer of Choice and for Its Creative and Digital Services: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
First Half of 2023 Sees ICON Recognised for CRO Excellence, Alongside Industry Awards as an Employer of Choice and for Its Creative and Digital Services


ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has received positive recognition from leading business and industry organisations as a leading

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Chemed To Report Second-Quarter 2023 Earnings July 26, Related Conference Call To Be Held On July 27:
Chemed To Report Second-Quarter 2023 Earnings July 26, Related Conference Call To Be Held On July 27


Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the second quarter ended June 30, 2023, on Wednesday, July 26, 2023, following the close of trading on the

Convatec Group PLC: Holding(s) in Company
Convatec Group PLC: Holding(s) in Company
Convatec Group PLC: Holding(s) in Company
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Almirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis: https://mms.businesswire.com/media/20221109006035/en/1631769/5/ALM_AW_LOGO_Tagline_MV_Positive_RGB_%281%29.jpg
Almirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis


Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced that Ilumetri® (tildrakizumab) significantly improved wellbeing in patients with

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Acadia Healthcare Announces Date for Second Quarter 2023 Earnings Release: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Announces Date for Second Quarter 2023 Earnings Release


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its second quarter 2023 results on Thursday, July 27, 2023, after the close of the market. Acadia will conduct a

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Invitation to Cosmo’s Half-Year 2023 Webcast on 26 July 2023
Invitation to Cosmo’s Half-Year 2023 Webcast on 26 July 2023
Invitation to Cosmo’s Half-Year 2023 Webcast on 26 July 2023